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METHODS: A published economic simulation model of
diabetes has been modified to allow for the calculation of
the costs of glycemic management and of treating dia-
betic complications over time. Age, gender, racial compo-
sition, cardiovascular risk factors and glycemic parame-
ters were taken from a recent clinical trial in diabetic
patients. The risks of complications were derived from
epidemiological studies. Costs of management of diabetes
and its complications were based on French tariffs, pub-
lished literature, and expert opinion. A cohort of 10,000
diabetic patients was simulated for 30 years. Future costs
were discounted at 5% per year.
RESULTS: On average, the cumulative direct medical
costs of managing diabetes and treating complications ac-
crue to FFR 103,431 (€15,767) per patient. During the
first eight years, more than 50% of the total costs are at-
tributed to the treatment of macrovascular complica-
tions, stroke and myocardial infarction. Over more than
20 years, the cost of microvascular complications will
rise to over 50%, driven primarily by the cost of end-
stage renal disease. The cost of managing diabetes will re-
main at approximately 10% of the total cost throughout
the model period.
CONCLUSIONS: Treatment of macrovascular complica-
tions dominates the total cost of diabetes over the first de-
cade. Only after 20 years or more of treatment do the costs
of microvascular complications become more important.
Thus, the focus should be on efforts to reduce the risks of
stroke and myocardial infarction in these patients.
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OBJECTIVE: To quantify use of health-care resources
for management of severe hypoglycaemia.
METHODS: We defined severe hypoglycaemia as an epi-
sode of coma or seizure requiring assistance from NHS
personnel. We excluded any episodes managed exclu-
sively by persons outside the health services. We included
all patients with Type 1 or Type 2 diabetes registered
with DARTS (Diabetes Audit and Research in Tayside
Scotland) and receiving treatment with insulin or oral hy-
poglycaemic drugs from June 1, 1997 to May 31, 1998.
We identified episodes from the records of three acute-
care hospital emergency rooms, eight minor injury units
in primary-care hospitals and from Tayside Ambulance
Service records.
RESULTS: Over 150,000 records were searched to iden-
tify 295 people with one or more episodes, of which 39
were excluded because they were not residents of Tayside
and another 12 because their identity could not be reli-
ably confirmed. The incidence of major hypoglycaemia
per 100 patient years was 12.0 (95% CI 8.2-13.7) in
Type 1 diabetics, 6.8 (CI 5.2-8.9) in Type 2 diabetics tak-
ing insulin and 0.8 (CI 0.6-1.0) in Type 2 diabetics on
oral hypoglycaemics. Fifty-two patients required inpa-
tient treatment. This compares with an incidence of 2.3
per 100 patient years for patients treated with insulin in
the UKPDS trial and 5.4 in the conventional arm of the
DCCT trial. The total health-care costs were £115,541 of
which 64% was for inpatient stay, 25% for ambulance
and 11% for emergency room.
CONCLUSIONS: The incidence of hypoglycaemia was
three- to five-fold higher than previously reported in clin-
ical trials, and extrapolation of our costs suggests that
hypoglycaemia could cost the UK NHS as much as
£16.2m per year.
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OBJECTIVE: Prospective studies like UKPDS have
shown that improved glycemic control in diabetic pa-
tients can reduce the risk of micro- and macrovascular
complications. To estimate the potential savings to health-
care systems due to interventions aimed at improving gly-
cemic control, the cost of complications must be known.
The objective of this study was to assess the cost of com-
plications in type 2 diabetic patients in the Netherlands.
METHODS: A review of published literature and guide-
lines was combined with data from ongoing research
projects and expert interviews to define the management
patterns for diabetic complications. Data from detailed
cost studies were used to estimate the Event cost (i.e.,
acute and post-acute care cost in the first year) and State
cost (i.e., subsequent recurring annual cost) of complica-
tions in 2000 NLG.
RESULTS: The cost of nephropathy was dominated by
the State cost of end stage renal disease (NLG 132,692).
Event and State costs due to retinopathy were relatively
low, except for the State cost of blindness (NLG 5,000).
Lower extremity amputation costs NLG 33,683 per event
and NLG 1,148 per year for subsequent management.
The event cost for AMI and stroke were NLG 21,877
and NLG 39,867, respectively. The subsequent State
costs were estimated at NLG 4,286 and NLG 16,131.
Over a simulated 30-year time horizon, the cost due to
macrovascular complications would account for 46% of
the total cost of complications discounted at 4%.
CONCLUSION: The cost of diabetic complications in
the Netherlands is substantial. Interventions that improve
glycemic control, and moreover, that affect the incidence
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of end stage renal disease, AMI or stroke are likely to re-
sult in substantial cost-offsets.
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OBJECTIVE: The UK Prospective Diabetes Study (UKPDS)
has proven the relevance of an intensive glucose control
policy in type 2 diabetes. UKPDS 35 has provided the evi-
dence of a significant association between diabetes-related
complications and level of HbA1c. We used the UKPDS
findings to assess the cost-effectiveness of a new fixed-dose
combination of metformin and glibenclamide, compared
to the conventional strategy of the UKPDS.
METHODS: We developed a Markov model reflecting
the management of two diabetic cohorts. The follow-up
of a cohort of newly diagnosed 50-year-old patients, sim-
ilar to the conventional group of the UKPDS, was simu-
lated to follow HbA1c progression over a 10-year period.
The second cohort, treated with metformin-glibencla-
mide, had the same demographic and clinical characteris-
tics at baseline. The reduction rate of HbA1c under met-
formin-glibenclamide was extracted from a 20-week
randomized double-blind trial. The HbA1c level in the
metformin-glibenclamide cohort was assumed to progres-
sively converge with that in the conventional group. The
occurrence of complications was modeled through risk
functions linking HbA1c levels to a conditional probabil-
ity using UKPDS 23 and 35 results. Results were com-
puted in a French context using a payer perspective. Only
medical costs were considered. A sensitivity analysis was
performed on the reduction rate of HbA1c under met-
formin-glibenclamide between 0.8 (best case) and 1.5
(worst case).
RESULTS: Cumulative medical costs amounted to EUR
7,240 in the conventional group versus EUR 7,759 in the
metformin-glibenclamide group. A 6.1% decrease in the
mean number of events per patient was obtained. The ad-
ditional cost per life year saved was EUR 13,142 (9,924
(best case), 17,912 (worst case)) and the additional cost
per complication-free year was EUR 5,736 (4,312 (worst
case), 7,842 (best case)).
CONCLUSION: These results suggest that metformin-
glibenclamide is cost-effective in the treatment of type 2
diabetes when compared with conventional therapy.
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OBJECTIVE: To assess the cost-effectiveness of pioglita-
zone (PIO) based combinations versus alternatives for pa-
tients with type 2 diabetes in Norway.
METHODS: A published/validated model for type1 dia-
betes developed by IMIB was adapted to simulate long-
term management, health outcomes, resource utilisation
and treatment costs of patients with type2 diabetes. The
model accounts for most complications in diabetes pa-
tients: nephropathy; retinopathy; acute myocardial in-
farction; angina pectoris; stroke, and amputation. The
analysis was done from third-party-payer perspective and
costs figured relative to the year 2000. A 5% discount
rate was applied and sensitivity analysis was done to test
the results.
RESULTS: Pioglitazone PIO 30 mg and metformin (MF)
were associated withlonger life expectancy (16.10 years)
than sulphonylureas(SU)/MF (15.24) or rosiglitazone
(RSG)/MET (15.95). PIO 30 mg/SU and PIO 15 mg/SU
are associated with the lowest number of serious compli-
cations per 100 patients treated. For every 95 patients
treated with PIO 30 mg/MF rather than SU/MF or every
27 patients, respectively, for PIO,30 mg/SU rather MF/SU,
one complication is avoided. Combinations of PIO 30
mg/SU, PIO 30 mg/MF and PIO 15 mg/SU are associated
with lower mortality than the other treatment combina-
tions available. Thus, for every 34 patients treated with
PIO 30 mg/MF rather than SU/MF, one death will be
avoided after 15 years of treatment. After discounting
both costs and life years at 5%, the above incremental
cost-per-life-year is 29,406 Norway Kroner (NOK) in
comparison to SU/MF, but still PIO dominates the com-
bination therapy with RSG 8 mg. The picture is similar in
the case of PIO 30 mg/SU combination compared to
MFSU, where in the undiscounted incremental cost per
life year gained, PIO dominates, and the cost per life year
gained is raised to 25,992 NOK after discounting at 5%.
CONCLUSION: Pioglitazone-based treatment for pa-
tients with type2 diabetes improves survival and reduces
complications and therefore represents a cost-effective
use of health-care resources in Norway. Nonetheless,
these results must be confirmed by long-term observa-
tional studies.
PDG12
CLINICAL BENEFITS AND COST-OFFSETS OF 
COMBINATION THERAPY WITH NATEGLINIDE 
PLUS METFORMIN VERSUS METFORMIN ALONE 
IN DIABETES IN THE NETHERLANDS
van den Boom G1, Koopmanschap MA2, Caro J3, Grueger J4
1Novartis Pharma, Arnhem, Netherlands; 2Erasmus University, 
Rotterdam, Netherlands; 3Caro Research Institute, Concord, 
MA, USA; 4Novartis Pharmaceuticals AG, Basel, Switzerland
OBJECTIVE: The objective of this study is to assess the
